<unk>  is an experimental drug with reported effects against both Alzheimer's disease and ageing in mouse models of accelerated aging. The approach that lead to development of the<unk>  drug was to screen candidate molecules for anti-aging effects, instead of targeting the amyloid plaques. It is contrary to most other approaches to developing drugs against Alzheimer's disease that target the plaque deposits in the brain. The<unk>  drug is also reported to address other biological aging factors, such as preventing the leakage of blood from microvessels in mice brains. The development of<unk>  follows the chemical pharmacological way, contrary to biological ways that exploit e.g. use of bacteriophages. Enhanced neurogenic activity over<unk>  in human neural precursor cells has its derivative called CAD-31. CAD-31 is enhancing the use of free fatty acids for energy production by shifting of the metabolic profile of fatty acids toward the production of ketone bodies, a potent source of energy in the brain when glucose levels are low. The target molecule is a protein called ATP synthase, which is found in the mitochondria.
J147
A-234 
A-232
Sim4
A-242
A-262
A-230
VX 